Independent Online

Tuesday, July 5, 2022

Like us on FacebookFollow us on TwitterView weather by locationView market indicators

Omicron-specific Sinopharm, Sinovac Covid-19 vaccine candidates cleared for clinical trial

A healthcare worker prepares a dose of China's Sinovac Biotech vaccine for the coronavirus disease (COVID-19) at a drive-thru vaccination station, in Jakarta, Indonesia. Picture: Reuters/Willy Kurniawan

A healthcare worker prepares a dose of China's Sinovac Biotech vaccine for the coronavirus disease (COVID-19) at a drive-thru vaccination station, in Jakarta, Indonesia. Picture: Reuters/Willy Kurniawan

Published Apr 16, 2022

Share

Covid-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday.

Scientists worldwide are racing to study upgraded injections against Omicron, as data indicated that antibodies elicited by vaccines based on older strains show weaker activity to neutralise the highly transmissible variant.

Story continues below Advertisement

The two candidates from units of Sinopharm subsidiary China National Biotec Group (CNBG) and one from Sinovac contain inactivated or "killed" coronavirus and are similar to vaccines that the companies are supplying in China and overseas, the companies said in statements.

The Sinopharm candidates will be tested as boosters in adults who have already received two or three vaccine doses, CNBG said. It did not specify which vaccine products the trial participants would have received before taking the experimental booster, or how many subjects would be recruited.

Sinovac said it will push forward studies in its existing CoronaVac vaccine's protection against emerging variants.

Story continues below Advertisement

A Chinese study showed that a fourth dose of BBIBP-CorV, an existing Sinopharm COVID vaccine, did not significantly lift antibody levels against Omicron when administered six months after a third booster dose to a regular two-dose regimen.

While the fourth dose restored antibody levels to around the peaks that followed the third dose, researchers said new vaccines would offer a better alternative as future boosters.

Reuters

Story continues below Advertisement

Share